CDS2 has attracted increasing attention recently as a potential target for anti-angiogenic treatment of tumours [36,37] and for treatment of uveal melanomas driven by mutationally enhanced PLC signalling [38]. This evidence concerns the gene HSPG2 and uveal melanoma.